CN104023713A - 用于治疗和/或预防天然ahr配体依赖性癌症的手段和方法 - Google Patents

用于治疗和/或预防天然ahr配体依赖性癌症的手段和方法 Download PDF

Info

Publication number
CN104023713A
CN104023713A CN201280043522.9A CN201280043522A CN104023713A CN 104023713 A CN104023713 A CN 104023713A CN 201280043522 A CN201280043522 A CN 201280043522A CN 104023713 A CN104023713 A CN 104023713A
Authority
CN
China
Prior art keywords
ahr
cancer
tdo
cells
kyn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280043522.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·普拉滕
C·奥皮茨
W·维克
U·利岑贝格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of CN104023713A publication Critical patent/CN104023713A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11011—Tryptophan 2,3-dioxygenase (1.13.11.11), i.e. indolamine 2,3-dioxygenase 2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11017—Indole 2,3-dioxygenase (1.13.11.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201280043522.9A 2011-09-07 2012-09-07 用于治疗和/或预防天然ahr配体依赖性癌症的手段和方法 Pending CN104023713A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161531861P 2011-09-07 2011-09-07
US61/531,861 2011-09-07
PCT/EP2012/067504 WO2013034685A1 (en) 2011-09-07 2012-09-07 Means and methods for treating and/or preventing natural ahr ligand-dependent cancer

Publications (1)

Publication Number Publication Date
CN104023713A true CN104023713A (zh) 2014-09-03

Family

ID=46832380

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280043522.9A Pending CN104023713A (zh) 2011-09-07 2012-09-07 用于治疗和/或预防天然ahr配体依赖性癌症的手段和方法

Country Status (15)

Country Link
US (1) US9593062B2 (https=)
EP (1) EP2753315B1 (https=)
JP (1) JP6047160B2 (https=)
KR (1) KR20140074330A (https=)
CN (1) CN104023713A (https=)
AU (1) AU2012306285B2 (https=)
BR (1) BR112014004937A2 (https=)
CA (1) CA2846275C (https=)
ES (1) ES2626015T3 (https=)
HK (1) HK1201471A1 (https=)
IL (1) IL231107A (https=)
MX (1) MX348941B (https=)
RU (1) RU2640913C2 (https=)
WO (1) WO2013034685A1 (https=)
ZA (1) ZA201401011B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106214673A (zh) * 2016-08-31 2016-12-14 深圳市第二人民医院 表没食子儿茶素没食子酸酯在制备预防或治疗膀胱肿瘤的药物中的用途
CN107510694A (zh) * 2016-06-16 2017-12-26 中国科学院上海巴斯德研究所 激活潜伏感染的艾滋病病毒的化合物及其在艾滋病治疗中的应用
CN109813913A (zh) * 2019-01-31 2019-05-28 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的新应用
CN112807305A (zh) * 2020-12-31 2021-05-18 中国科学院生态环境研究中心 Ch223191在抑制肿瘤细胞迁移中的应用
CN114019164A (zh) * 2020-12-31 2022-02-08 中国科学院生态环境研究中心 筛选抗胶质瘤药物的方法和试剂盒
CN114470238A (zh) * 2022-03-25 2022-05-13 华中科技大学同济医学院附属协和医院 AhR抑制剂CH223191在制备抑制肿瘤相关巨噬细胞药物中的应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2953065B2 (ja) 1990-12-28 1999-09-27 石川島播磨重工業株式会社 宇宙飛翔体
KR102271498B1 (ko) * 2013-08-30 2021-07-05 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 종양 치료를 위한 키누레닌 고갈 효소의 투여
JP7080053B2 (ja) 2014-08-29 2022-06-03 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与
CA2980730A1 (en) 2015-03-23 2016-09-29 The Brigham And Women's Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
US11542486B2 (en) 2016-03-02 2023-01-03 Board Of Regents, The University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
WO2018085775A1 (en) * 2016-11-04 2018-05-11 Ohio State Innovation Foundation Methods and compositions for treating multiple myeloma and increasing antibody dependent cell cytotoxicity by targeting the aryl hydrocarbon receptor
WO2019036657A1 (en) * 2017-08-17 2019-02-21 Kyn Therapeutics AHR INHIBITORS AND USES THEREOF
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CA3096549A1 (en) 2018-04-16 2019-10-24 Board Of Regents, The University Of Texas System Human kynureninase enzymes and uses thereof
RU2699932C1 (ru) * 2018-11-14 2019-09-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ прогнозирования риска развития рака печени у экспериментальных животных
KR20220125323A (ko) * 2020-01-10 2022-09-14 이케나 온콜로지, 인코포레이티드 Ahr 억제제 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101466363A (zh) * 2006-05-03 2009-06-24 西姆莱斯有限责任两合公司 Ah受体拮抗剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
JP4587652B2 (ja) 2002-09-09 2010-11-24 株式会社フラバミン 新規フラボノイド化合物及びその利用
US20060135445A1 (en) * 2003-02-04 2006-06-22 Kabushiki Kaisha Yakult Honsha Breast cancer-resistant protein inhibitor
US20110159017A1 (en) 2008-04-11 2011-06-30 Ludwig Institute For Cancer Research Ltd. Trytophan catabolism in cancer treatment and diagnosis
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101466363A (zh) * 2006-05-03 2009-06-24 西姆莱斯有限责任两合公司 Ah受体拮抗剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JEONG-EUN TE AL.: "3’,4’-Dimethoxyflavone as an Aryl Hydrocarbon Receptor Antagonist in Human Breast Cancer Cells.Jeong-Eun te al.Toxicological Sciences.2000年，第58卷，第235-242页", 《TOXICOLOGICAL SCIENCES.》 *
MILLER ET AL.: "Benzo-[a]-pyrene increases invasion in MDA-MB-231 breast cancer cells via increased COX-II expression and prostaglandin E2 (PGE2) output. M.E. Miller et al. Clinical & Experimental Metastasis . 2005年第22卷第 149–156页", 《 CLINICAL & EXPERIMENTAL METASTASIS》 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107510694A (zh) * 2016-06-16 2017-12-26 中国科学院上海巴斯德研究所 激活潜伏感染的艾滋病病毒的化合物及其在艾滋病治疗中的应用
CN107510694B (zh) * 2016-06-16 2022-03-29 中国科学院上海巴斯德研究所 激活潜伏感染的艾滋病病毒的化合物及其在艾滋病治疗中的应用
CN106214673A (zh) * 2016-08-31 2016-12-14 深圳市第二人民医院 表没食子儿茶素没食子酸酯在制备预防或治疗膀胱肿瘤的药物中的用途
CN109813913A (zh) * 2019-01-31 2019-05-28 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的新应用
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
CN112807305A (zh) * 2020-12-31 2021-05-18 中国科学院生态环境研究中心 Ch223191在抑制肿瘤细胞迁移中的应用
CN114019164A (zh) * 2020-12-31 2022-02-08 中国科学院生态环境研究中心 筛选抗胶质瘤药物的方法和试剂盒
CN114019164B (zh) * 2020-12-31 2023-11-21 中国科学院生态环境研究中心 筛选抗胶质瘤药物的方法和试剂盒
CN114470238A (zh) * 2022-03-25 2022-05-13 华中科技大学同济医学院附属协和医院 AhR抑制剂CH223191在制备抑制肿瘤相关巨噬细胞药物中的应用

Also Published As

Publication number Publication date
BR112014004937A2 (pt) 2017-06-20
ES2626015T3 (es) 2017-07-21
CA2846275C (en) 2019-07-16
KR20140074330A (ko) 2014-06-17
EP2753315B1 (en) 2017-03-01
MX2014002776A (es) 2014-11-25
US20140294860A1 (en) 2014-10-02
JP2014526450A (ja) 2014-10-06
MX348941B (es) 2017-07-04
AU2012306285B2 (en) 2017-05-18
EP2753315A1 (en) 2014-07-16
CA2846275A1 (en) 2013-03-14
WO2013034685A1 (en) 2013-03-14
US9593062B2 (en) 2017-03-14
IL231107A (en) 2017-11-30
AU2012306285A1 (en) 2014-02-27
ZA201401011B (en) 2018-07-25
IL231107A0 (en) 2014-04-30
RU2640913C2 (ru) 2018-01-12
RU2014104696A (ru) 2015-10-20
HK1201471A1 (en) 2015-09-04
JP6047160B2 (ja) 2016-12-21

Similar Documents

Publication Publication Date Title
JP6047160B2 (ja) 天然ａｈｒリガンド依存性癌を治療および／または予防するための手段および方法
Li et al. Mex3a promotes oncogenesis through the RAP1/MAPK signaling pathway in colorectal cancer and is inhibited by hsa‐miR‐6887‐3p
Zhang et al. Renal cell carcinoma-derived exosomes deliver lncARSR to induce macrophage polarization and promote tumor progression via STAT3 pathway
Diedrich et al. Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1α activation
Mujcic et al. Hypoxic activation of the unfolded protein response (UPR) induces expression of the metastasis-associated gene LAMP3
Zhao et al. GAS5 suppresses malignancy of human glioma stem cells via a miR-196a-5p/FOXO1 feedback loop
Chai et al. Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133
Lei et al. Mitochondrial fission induces immunoescape in solid tumors through decreasing MHC-I surface expression
Liu et al. Candidate tumour suppressor CCDC 19 regulates miR‐184 direct targeting of C‐Myc thereby suppressing cell growth in non‐small cell lung cancers
Li et al. Long non-coding RNA SBF2-AS1 promotes hepatocellular carcinoma progression through regulation of miR-140-5p-TGFBR1 pathway
Zhu et al. Retracted: LncRNA AWPPH inhibits SMAD4 via EZH2 to regulate bladder cancer progression
Wang et al. Inhibition of EZH2 attenuates sorafenib resistance by targeting NOTCH1 activation-dependent liver cancer stem cells via NOTCH1-related MicroRNAs in hepatocellular carcinoma
Tao et al. ARHGAP25: A negative regulator of colorectal cancer (CRC) metastasis via the Wnt/β-catenin pathway
Wei et al. Signal Peptide Peptidase, Encoded by HM 13, Contributes to Tumor Progression by Affecting EGFR v III Secretion Profiles in Glioblastoma
Anania et al. Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells
Liu et al. Identification of circ-FNDC3B, an overexpressed circRNA in abdominal aortic aneurysm, as a regulator of vascular smooth muscle cells
Feng et al. KPNA4 regulated by miR-548b-3p promotes the malignant phenotypes of papillary thyroid cancer
He et al. Identification of novel biomarker hsa_circ_0003914 for rheumatoid arthritis from plasma exosomes
Jiang et al. miR-520f-3p blocks MNNG-induced gastric precancerous lesions via the KLF7/NFκB pathway
JP2017510261A (ja) 抗ｃｄ２０抗体を用いての処置に対する患者の応答性を予測するための方法
Xiao et al. Long non-coding HOXA-AS3 contributes to osteosarcoma progression through the miR-1286/TEAD1 axis
WO2010122135A2 (en) Use of mlkl in cancer therapy
Shi et al. Tumor-immune-neural circuit disrupts energy homeostasis in cancer cachexia
Yang et al. Circular RNA hsa_circ_0008003 promotes the progression of non–small‐cell lung cancer by sponging miR‐548I and regulating KPNA4 expression
Qian et al. PFOA exposure promotes prostate cancer progression by enhancing autophagy through m6A modification of MAPK15 mRNA

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201471

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140903

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1201471

Country of ref document: HK